- Business Wire•3 hours ago
Dr. Reddy’s Laboratories Ltd. announced today that it has entered into a strategic collaboration with Gland Pharma, a globally recognized developer and manufacturer of sterile dosage forms, to market and distribute a diverse portfolio of eight injectable Abbreviated New Drug Applications .
- Zacks•4 hours ago
Dr. Reddy's Laboratories Ltd. (RDY) reported second-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 27 cents, down 57.1% year over year.
- Barrons.com•23 hours ago
Earlier today, India’s second-largest drug maker, reported a fiscal second quarter quarterly profit that was below analysts' estimates due to a drop in sales, mainly in emerging markets. As Reuters reported: Net profit for the July-September quarter was 3.09 billion rupees ($46.20 million), while analysts, on average, had expected a profit of 3.5 billion rupees, according to Thomson Reuters data. Sales fell in most of Dr Reddy's markets, especially the emerging market countries that include Russia and Romania, where they were down 27 percent in value terms.
Dr. Reddy's Laboratories Ltd. (RDY)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||48.45 x 200|
|Ask||48.48 x 200|
|Day's Range||48.28 - 49.59|
|52wk Range||40.67 - 66.68|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||36.84|
|Avg Vol (3m)||315,361|
|Dividend & Yield||0.30 (0.65%)|